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INTRODUCTION
Primary central nervous system origin germ cell tumors
(CNS-GCTs) are rare. The incidence of CNS-GCTs is rela-
tively higher in Korea as well as Japan and Taiwan (1-3). In
the past, radiation therapy was used as a single modality for
the treatment of CNS-GCTs (4-12). Although 40 to 60 Gy
of local irradiation with variable doses of craniospinal irradi-
ation has been very effective in pure germinonas, the survival
rates of patients with nongerminonatous GCTs have been
relatively poor with the cure rate around 50%. In the 1980s,
investigators began to report the effectiveness of systemic
chemotherapy especially for nongerminomatous CNS-GCTs
(13-15). Until recently, a number of chemotherapeutic agents
have been used in various combinations, among which cis-
platin has been most frequently used. However, the optimal
therapeutic strategy for CNS-GCTs is not established yet.
Since September 1997, we have used front-line chemother-
apy followed by radiotherapy for pure germinomas as well
as nongerminomatous GCTs. The early treatment strategy
for these patients was to use uniform doses of chemotherapy
regardless of the differences in pathology and tumor marker
status, which was unsatisfactory. Thereafter, we tried to begin
risk-adapted strategy, which used higher doses of cytotoxic
agents with high-dose cisplatin-based intensified regimen
for high-risk patients. Unfortunately, we found, despite the
excellent response rate, unexpectedly high incidence of oto-
toxicity in patients who received high-dose cisplatin, which
urged us to revise the treatment protocol to a less ototoxic
carboplatin-based one.
In here, we report our single center experience using differ-
ent treatment protocols that have been evolved according to
the clinical requirements, and the impact of the change in
treatment policy on the outcomes of patients with malignant
CNS-GCTs.
MATERIALS AND METHODS
Patients and treatments
From September 1997 to September 2006, 55 patients with
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Improved Outcome of Central Nervous System Germ Cell Tumors:
Implications for the Role of Risk-adapted Intensive Chemotherapy
To determine the impact of treatment protocols on the outcome of central nervous
system germ cell tumors (CNS-GCTs), we reviewed the medical records of 53 pati-
ents who received front-line chemotherapy from September 1997 to September
2006. Pure germinoma, normal alpha-fetoprotein level and beta-human chorionic
gonadotropin level <50 mIU/mL were regarded as low-risk features and the others
as high-risk. Patients from different time periods were divided into 3 groups accord-
ing to the chemotherapy protocols. Group 1 (n=19) received 4 cycles of chemother-
apy comprising cisplatin, etoposide and bleomycin. Group 2 (n=16) and group 3
(n=18) received 4 cycles of chemotherapy with cisplatin, etoposide, cyclophospha-
mide and vincristine in the former and with carboplatin, etoposide, cyclophospha-
mide and bleomycin in the latter. In group 2 and group 3, high-risk patients received
double doses of cisplatin, carboplatin and cyclophosphamide. Radiotherapy was
given after chemotherapy according to the clinical requirements. The event-free
survivals of groups 1, 2, and 3 were 67.0%, 93.8%, and 100%, respectively (group
1 vs. 2, P=0.06; group 2 vs. 3, P=0.29; group 1 vs. 3, P=0.02). Our data suggest
that risk-adapted intensive chemotherapy may improve the outcome of patients
with malignant CNS-GCTs.
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newly diagnosed malignant CNS-GCTs received front-line
chemotherapy at our institution. Fifty-three patients were
analyzed and data from 2 patients were not included due to
early loss to follow-up against medical advice before comple-
tion of chemotherapy. When histologic confirmation was not
done, typical magnetic resonance imaging (MRI) scan find-
ings along with elevated tumor marker(s) such as alpha-feto-
protein (AFP) and/or beta-human chorionic gonadotropin
(bHCG) were used for diagnosis. Evaluations using brain
MRI, whole spine MRI, cerebrospinal fluid (CSF) cytology,
and tumor marker levels in serum and CSF were performed
in all patients prior to the initiation of chemotherapy. Patients
were divided into either low-risk or high-risk groups. The
low-risk criteria were defined as follows; 1) pure germinoma
confirmed by histology, 2) normal AFP level, and 3) low serum
and CSF bHCG level (<50 mIU/mL). All the others who did
not meet any of the low-risk criteria were regarded as high-
risk considering that some patients with histologically proven
germinoma have elevated AFP and high bHCG levels, which
suggest they actually possess nongerminomatous components
in their unbiopsied sites. For the analysis of treatment out-
come, patients from different time periods were divided into
3 groups according to the differences in chemotherapy pro-
tocols. Group 1 (from Septmeber 1997 to September 2002;
n=19) received 4 cycles of chemotherapy (cisplatin 100 mg/
m2 on day 0, etoposide 100 mg/m2 from day 0 to 4, bleomy-
cin 15 mg/m2 on day 0) named ‘‘PEB’’ every 3 weeks irrespec-
tive of their risk status. For group 2 (from October 2002 to
July 2004; n=16) and group 3 (from August 2004 to Septem-
ber 2006; n=18), risk-adapted chemotherapies were given
with cisplatin, etoposide, cyclophosphamide and vincristine
(CECO) in the former and with carboplatin, etoposide, cyclo-
phosphamide and bleomycin (CECB) in the latter-high-risk
patients received double doses of cisplatin, carboplatin and
cyclophosphamide. In addition, bleomycin was added to the
high-risk patients in group 3. Details of risk-adapted chemo-
therapy are illustrated in Fig. 1. The CECO or CECB regi-
mens were composed of 2 different schedules alternating every
3 week intervals and were completed after 4 cycles. All radio-
therapy was given after chemotherapy and was individualized
according to the clinical requirements (Table 1). The radio-
therapy was delivered to the local field with or without cran-
iospinal irradiation. The protocols used were approved by the
Institutional Review Board of Samsung Medical Center (2008-
11-056, 2009-02-050) and informed consent was obtained
from the patients and/or guardians before starting treatments.
Evaluation for response and toxicity of chemotherapy
Response to chemotherapy was determined by MRI and
tumor marker measurements. The radiologic response was
defined as follows: complete response (CR), no radiographic
evidence of residual tumor and normal tumor marker(s); par-
tial response (PR), more than 50% reduction in tumor vol-
ume with at least 50% reduction of tumor marker(s); stable
disease (SD), less than 50% reduction in tumor volume or less
than 25% increase in any measurable tumor area without an
substantial increase in tumor marker(s); progressive disease
(PD), more than 25% increase in measureable tumor size and/
or substantial elevation of tumor marker(s). Considering that
a significant proportion of GCTs remain remnant lesion des-
pite complete regression of viable tumors, we regarded a non-
secreting remnant visible tumor without any increase in size
for at least 2 yr after a completion of treatment as a clinical
CR. When a significantly large tumor removed after chemo-
therapy and before radiotherpay revealed no viable tumor
cells, it was also regarded as a clinical CR. Hematologic and
non-hematologic toxicities were assessed by blood tests, clin-
ical symptoms or signs, and specific tests if needed. Toxicity
was graded using the National Cancer Institute Common
Toxicity Criteria version 3.0.
Supportive care
Patients receiving cisplatin were adequately hydrated with
intravenous fluids. When diabetes insipidus was present, oral
Fig. 1. Risk-adapted chemotherapy. CECO regi-
men is for group 2 and CECB regimen for group
3. In each regimen, course [a] and course [b]
were administered alternatively as ‘[a]-[b]-[a]-[b]’
every 3 week intervals and were completed after
4 cycles in total. 
*For high-risk patients. 
CDDP, cisplatin; VP-16, etoposide; VCR, vincris-
tine; CPM, cyclophosphamide; CBDCA, carbo-
platin; Bleo, bleomycin.
Course [a]
Day 0 1 2 3 4
CECO
CDDP 20 (40*) mg/m
2/day
VP-16 100 mg/m
2/day
CDDP
VP-16
Course [a]
Day 0 1 2
CECB
CBDCA 450 mg/m
2/day
VP-16 150 mg/m
2/day
Bleo 15 mg/m
2/day
CBDCA
VP-16
Bleo
Course [b]
Day 0 1 2
VP-16 150 mg/m
2/day
CPM 1(2*) g/m
2/day
Bleo 15 mg/m
2/day
VP-16
CPM
Bleo
Course [b]
Day 0 1 ... 7 ... 14
VCR 1.5 mg/m
2/day
CPM 1 (2*) g/m
2/day
VCR
CPM
*
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desmopression was used to maintain the input/output bal-
ance. When the neutrophil count fell below 0.5×109/L, pati-
ents received granulocyte colony-stimulating factor (G-CSF)
daily until it reached above 1.0×109/L. Irradiated (25 Gy)
red blood cells or platelet concentrates were transfused to main-
tain the hemoglobin level above 8.0 g/dL and the platelet count
above 20×109/L.
Statistical analysis
Fisher’s exact test or chi-square test and Mann-Whitney
U-test were used for a comparison of frequencies and observ-
ed values between groups. A P value <0.05 was considered
as significant. The Kaplan-Meier estimates of overall survival
(OS) and event-free survival (EFS) were used throughout the
analysis and were calculated from the date of diagnosis to the
date of last follow-up or event. An event was defined as dis-
ease recurrence, progression, or death from any cause. Survival
curves were compared by the log-rank test. Statistical analy-
sis was performed with the SPSS software version 12.0.
RESULTS
Patient characteristics
The median age at diagnosis was 13.8 yr (range, 6.4-22.4)
and the male to female ratio was 2.8:1. Clinicopathologic char-
acteristics are detailed in Table 2. Histologic diagnosis was
obtained in 51 patients by endoscopic (n=28), stereotactic
(n=12), open (n=10), or transsphenoidal (n=1) biopsy. No
tumors were totally removed before chemotherapy. Two pati-
ents were diagnosed with a typical MRI finding and tumor
marker elevation without a tissue diagnosis. On histologic
examination, 40 patients had germinomas and 11 were proven
to have nongerminomatous GCTs. Two patients without a
tissue diagnosis had significantly elevated tumor markers. In
addition to 11 patients with biopsy-proven nongerminoma-
tous GCTs, 2 patients having secreting tumors (bHCG lev-
els 3 887 and 123 mIU/mL in CSF, respectively) without his-
tologic comfirmation and 13 patients with biopsy-proven
germinoma but having elevated AFP and/or bHCG ≥50
mIU/mL were also regarded as high-risk. Accordingly, 26
patients (49.1%) were allocated to the high-risk category. The
demographic composition of each group is shown in Table 3.
The frequency of high-risk patients in each group was not
statistically different (group 1 vs. 2, P=0.37; group 1 vs. 3,
P=0.60; group 2 vs. 3, P=0.20). The most common site of
tumor involvement was pineal gland and almost a half of pati-
ents (45.3%) had diabetes insipidus at initial presentation.
AFP and/or bHCG were significantly elevated in 45.3% of
patients. CSF cytology revealed negative in all cases.
Response to chemotherapy
Radiologic responses and clinical CR rates are listed in
Table 4. Among the 24 patients who had significantly ele-
vated tumor marker(s) at initial diagnosis, 22 (91.7%) show-
ed complete normalization of the tumor marker(s), and it was
100% in both group 2 and 3. The majority of patients res-
ponded to chemotherapy and no patients showed disease pro-
gression during chemotherapy. Two patients in group 1 were
not evaluable for radiologic response due to a premature death
during chemotherapy. The high-risk patients in group 3 show-
ed better clinical CR rate when compared with those in group
1 (85.7% vs. 22.2%, P=0.04). 
*Four patients did not receive radiation therapy due to premature death (2 in group 1), progression after second-look surgery (1 in group 2), or morbidi-
ty by tumor bleeding (1 in group 3); 
�
P value <0.05 when compared with corresponding values of group 1. 
Group 1 (n=19)
RT
High-risk Low-risk Total
Group 2 (n=16)
High-risk Low-risk Total
Group 3 (n=18)
High-risk Low-risk Total
No. of patients: RT not done* 1 1 2 1 0 1 1 0 1
No. of patients: RT done 8 9 17 9 6 15 6 11 17
Median RT dose, Gy (range)
Craniospinal 15 0  0 36  19.5  19.5  21.5  19.5 19.5 
(0-36) (0-23.4) (0-36) (19.5-39) (0-19.5) (0-39)
� (19.5-36) (0-24)
� (0-36)
�
Local 19 30  20  18 19.8  18 13.5  19.8  16.2 
(10-40) (10-40) (10-40) (10-20) (10.8-30) (10-30) (10.8-18) (10.8-30.6) (10.8-30.6)
Tumor bed in total 45  30  30  54  34.8  39.3  35  39.3  39.3 
(30-56) (30-41.4) (30-56) (30-57) (30-39.3) (30-57) (30.3-54) (28.8-41.4) (28.8-54)
Mean RT dose, Gy
Craniospinal 16.6 2.6 9.2 30.2 13.0 23.3 25.7 17.4 20.3
Local 19.3 25.3 22.5 16.7 21.7 18.7 14.1 19.0 17.3
Tumor bed in total 43.8 32.4 37.8 47.0 34.7 42.5 39.8 36.4 37.6
Table 1. Radiotherapy (RT) in each group of patientsRisk-adapted Chemotherapy for CNS-germ Cell Tumor 461
Second-look operation
Second-look surgery was performed in 4 high-risk patients
(1 in group 1, 2 in group 2, 1 in group 3) who had a signif-
icantly large residual tumor after chemotherapy, which reveal-
ed no viable tumor cells in 2 patients; one from choriocarci-
noma to mature teratoma, and the other from immature ter-
atoma to mature teratoma. The other 2 patients (1 in group
1, 1 in group 2) having viable malignant cells eventually died
despite post-surgery irradiation and high-dose chemothera-
py, one from disease progression and the other from treatment-
related toxicities.
Toxicities of chemotherapy
Most patients (96.2%) developed grade 4 neutropenia and
41 patients (77.4%) required hospitalization due to neutro-
penic fever at least once. The incidence of neutropenic fever
defined as ‘total episodes of neutropenic fever per total num-
ber of chemotherapy cycles’ was significantly higher in group
2 (66.1%) and group 3 (51.4%) when compared with group
1 (21.9%). The relative risk of neutropenic fever in group 2
over group 1 was 2.67 ([95% CI, 1.79-3.99], P<0.001), group
3 over group 1 was 1.84 ([95% CI, 1.33-2.52], P=0.001),
and group 2 over group 3 was 1.40 ([95% CI, 0.94-2.01],
P=0.08), respectively. All the episodes of neutropenic fever
were manageable without significant complications except
in one episode which was associated with mortality in group
1. The incidence of grade 3 or 4 thrombocytopenia was also
higher in group 2 (87.5%) and group 3 (88.9%) than that
of group 1 (31.6%). Four high-risk patients in group 2 who
received 2 cycles of high-dose cisplatin (200 mg/m2/cycle)
developed high-frequency sensorineural hearing loss, 3 of
whom had diabetes insipidus. One patient with choriocarci-
noma in group 3 became in bed-ridden state due to massive
tumor bleeding which happened during chemotherapy, but
showing normal bHCG level and no evidence of tumor pro-
gression at 44 months after diagnosis.
Events and survival
In group 1, four patients relapsed, one prematurely died
due to uncontrolled increased intracranial pressure, and ano-
ther died from infectious complications. In group 2, the one
and only event was tumor recurrence. The patient eventual-
ly died from disease progression after high-dose chemother-
apy and autologous stem cell rescue. There was no event in
group 3. The 5-yr OS and EFS of 53 patients were 90.6%
and 85.5%, respectively, with a median follow-up of 59 mon-
ths (range, 22-124) from the diagnosis (Fig. 2A). The low-
AFP, alpha-fetoprotein; bHCG, beta-human chorionic gonadotropin.
Characteristics No. of patients (%)
Sex
Male 39 (73.6)
Female 14 (26.4)
Symptoms or signs
Visual dysfunction 32 (60.4)
Headache 31 (58.5)
Vomiting 25 (47.2)
Diabetes insipidus 24 (45.3)
Motor disturbance 15 (28.3)
Obtundation 4 (7.5)
Precocious puberty 4 (7.5)
Short stature 3 (5.7)
Tumor markers
AFP elevation+bHCG <50 mIU/mL 5 (9.4)
AFP elevation+bHCG ≥50 mIU/mL 7 (13.2)
bHCG ≥50 mIU/mL+normal AFP 12 (22.6)
bHCG <50 mIU/mL+normal AFP 29 (54.7)
Tumor location
Pineal (P) 19 (35.8)
Sellar or suprasellar (S) 13 (24.5)
Thalamus (T) or basal ganglia (BG) 7 (13.2)
Ventricle (V) 1 (1.9)
S+BG 1 (1.9)
P+S 7 (13.2)
P+V 1 (1.9)
Multiple 4 (7.5)
Histology
Germinoma (G) 40 (75.5)
Endodermal sinus tumor (EST) 1 (1.9)
Choriocarcinoma (CC) 2 (3.8)
Immature teratoma (IT) 2 (3.8)
Embryonal carcinoma (EC) 0 (0)
G+EST 2 (3.8)
G+IT 1 (1.9)
IT+EST 2 (3.8)
EC+EST 1 (1.9)
Unknown (biopsy not performed) 2 (3.8)
Risk group
High-risk 26 (49.1)
Low-risk 27 (50.9)
Table 2. Clinical characteristics of subjected patients (n=53)
*AFP elevation and/or bHCG ≥50 mIU/m.
Parameters
No. of patients
Group 1 
(n=19)
Group 2 
(n=16)
Group 3 
(n=18)
Tumor marker elevation*
Yes 9 9 6
No 10 8 12
Histology
Germinoma 16 9 15
Nongerminomatous 3 5 3
Unknown 0 2 0
Risk group
High-risk 9 10 7
Low-risk 10 6 11
Table 3. Number of patients by tumor marker, histology, and risk462 K.H. Yoo, S.H. Lee, J. Lee, et al.
risk patients showed better EFS than the high-risk patients
although it was not statistically significant (Fig. 2B). In group
1, the high-risk patients showed inferior EFS compared to
the low-risk patients without a statistical significance (Fig.
3A). In group 2 and group 3, even the high-risk patients
showed excellent EFS (Fig. 3B, C). The event-free survival
of group 1, group 2, and group 3 were 67.0%, 93.8%, and
100%, respectively (group 1 vs. 2, P=0.06; group 2 vs. 3,
P=0.29; group 1 vs. 3, P=0.02) (Fig. 3D). All patients in
group 3 are alive event-free with a median follow-up of 36
months (range, 26-51).
DISCUSSION
Malignant CNS-GCTs have been classified as germinomas
vs. nongerminomatous GCTs or secreting vs. non-secreting
tumors. However, such classifications have limitations since
biopsy-proven germinomas can have nongerminomatous ele-
ments among the unbiopsied sites and non-secreting tumors
can also have nongerminomatous components such as imma-
ture teratoma with less favorable prognosis (16). It is well-
known that both nongerminonatous and secreting GCTs have
worse prognosis. Therefore, we regarded those as high-risk
either having nongerminomatous components or having ele-
vated AFP or bHCG ≥50 mIU/mL. Considering that ger-
*Of 24 patients (9 in group 1, 9 in group 2, 6 in group 3) whose tumor marker(s) at initial diagnosis were significantly elevated (AFP elevation and/or bHCG
≥50 mIU/mL); 
�
Values when compared with each risk group and total patients in group 1.
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.
No. patients (%)
Parameters
Group 1
High-risk
(n=9)
Low-risk
(n=10)
Total
(n=19)
Group 2
High-risk
(n=9)
Low-risk
(n=10)
Total
(n=19)
Group 3
High-risk
(n=9)
Low-risk
(n=10)
Total
(n=19)
Tumor marker*
Normalized 7 (77.8) - 7 (77.8) 9 (100) - 9 (100) 6 (100) - 6 (100)
Partially decreased 1 (11.1) - 1 (11.1) 0 (0) - 0 (0) 0 (0) - 0 (0)
Increased 0 (0) - 0 (0) 0 (0) - 0 (0) 0 (0) - 0 (0)
Not evaluable 1 (11.1) - 1 (11.1) 0 (0) - 0 (0) 0 (0) - 0 (0)
Radiologic response
CR 0 (0) 2 (20) 2 (10.5) 4 (40) 1 (16.7) 5 (31.3) 2 (28.6) 5 (45.5) 7 (38.9)
PR 5 (55.6) 8 (80) 13 (68.4) 5 (50) 5 (83.3) 10 (62.5) 4 (57.1) 6 (54.5) 10 (55.6)
SD 2 (22.2) 0 (0) 2 (10.5) 1 (10) 0 (0) 1 (6.3) 1 (14.3) 0 (0) 1 (5.6)
PD 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Not evaluable 2 (22.2) 0 (0) 2 (10.5) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Clinical CR
P value
� 2 (22.2) 6 (60) 8 (42.1) 7 (70) 2 (33.3) 9 (56.3) 6 (85.7) 10 (90.9) 16 (88.9)
--- 0.07 0.6 0.4 0.04 0.15 0.005
Table 4. Number of patients by response after treatment
Fig. 2. The Kaplan-Meier estimate of survival. The 5-yr overall survival (OS) and event-free survival (EFS) of 53 patients were 90.6% and
85.5%, respectively (A). Low-risk patients show better EFS than high-risk patients (92.6% vs. 79.3%, P=0.24) without a statistical signifi-
cance (B).
A
P
r
o
b
a
b
i
l
i
t
y
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
0 12 24 36 48 60 72 84 96 108 120
Months after diagnosis
OS
B
P
r
o
b
a
b
i
l
i
t
y
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
0 12 24 36 48 60 72 84 96 108 120
Months after diagnosis
EFS
High-risk (n=26)
Low-risk (n=27)
P=0.24Risk-adapted Chemotherapy for CNS-germ Cell Tumor 463
minomas can secrete small amount of bHCG, a relatively low
bHCG level (<50 mIU/mL) was not included in the high-
risk criteria.
Our risk-adapted chemotherapy strategy produced very
high clinical CR rate when we included those having a radi-
ological remnant tumor into the complete responders provid-
ed that it was considered nonevolving. Assessing the response
of GCTs is frequently confusing because treated GCTs tend
to remain as remnant fibrotic, calcified, cystic or fully differ-
entiated mass but actually containing no viable tumor cells.
Therefore, we also regarded those as clinical complete respon-
ders who had a small residual lesion with normal tumor marker
levels at the end of chemotherapy, provided that the lesion did
not show any increase in size without any elevation of tumor
markers for more than 2 yr after a completion of irradiation.
In fact, 2 of 4 patients in this study who underwent second-
look surgery after chemotherapy had no viable tumor cells
despite a significantly large residual tumor size after chemo-
therapy. 
Because of the rarity of these tumors and a lack of large
prospective studies, the optimal therapeutic strategy for malig-
nant CNS-GCTs remains unsettled. An early study by Rich
et al. (5) suggested that nongerminomatous or secreting tumors
were relatively resistant to radiotherapy. After the chemother-
apy was introduced as a treatment modality for gonadal GCTs,
the efficacy of chemotherapy for CNS-GCTs has been tested
by many investigators. In 1995, Itoyama et al. (17) showed
the effectiveness of multidisciplinary treatment including
combination chemotherapy in treating AFP-producing CNS-
GCTs. In the next year, the International Central Nervous
System Germ Cell Tumor Study Group reported the results
of an international cooperative trial using chemotherapy with-
out irradiation, which showed 78% of CR rate (84% for ger-
minoma, 78% for nongerminomatous GCTs) (18). Howev-
er, 49% of the complete responders in their study eventual-
ly relapsed, which implicates the indispensible role of radio-
therapy. The importance of radiotherapy was confirmed again
in a study, in which patients with secreting CNS-GCTs were
treated with chemotherapy alone, but unfortunately 12 of the
13 non-irradiated patients eventually relapsed (19). On the
other hand, a study by Robertson et al. (20) using ‘sandwich’
therapy (chemotherapy-radiation-chemotherapy) showed 67%
of 4-yr EFS among 18 nongerminomatous GCT patients and
they concluded that the multi-modality adjuvant therapy
approach appeared to dramatically improve the prognosis of
these tumors. More recently, clinical trials using systemic
chemotherapy combined with radiotherapy showed clear ben-
efits over the strategy using radiotherapy alone especially for
nongerminomatous GCTs. Matsutani et al. (21) conducted
a multiinstitutional phase II study to establish a postsurgi-
cal combined chemotherapy and radiotherapy, and conclud-
ed that their protocols were effective for patients with germi-
Fig. 3. The Kaplan-Meier estimate of event-free survival (EFS). In group 1, the high-risk patients show inferior EFS compared to the low-risk
patients without a statistical significance (A). In group 2 (B) and group 3 (C), even the high-risk patients show excellent EFS. The EFS of
group 3 is superior to that of group 1 (P=0.02), while the difference between group 1 and group 2 (P=0.06) as well as group 2 and group
3 (P=0.29) do not show a statistical significance (D).
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nomas and those with an intermediate prognosis. A multi-
institutional retrospective analysis by Ogawa et al. (22) report-
ed a higher 5-yr survival rate in chemotherapy group than
that in non-chemotherapy group (84% vs. 44%). According
to the Children’s Oncology Group report in 2007 on the effi-
cacy of pre-radiation chemotherapy with response-based radi-
ation therapy in children with CNS-GCTs, although the num-
ber of patients was small (n=26), 3-yr OS was 100% for ger-
minomas and 79% for nongerminomatous GCTs (23).
In the current study, authors demonstrated an improvement
in the survival rate of our patients using risk-adapted inten-
sive chemotherapy in conjunction with subsequent radiother-
apy. Our early treatment outcomes using 4 cycles of PEB regi-
men prior to radiotherapy had resulted in unsatisfactory out-
come, which showed 67% of 5-yr EFS. Therefore we changed
the chemotherapy strategy to more intensive risk-adapted cis-
platin-based regimens. Although this change in treatment
strategy showed excellent survival outcomes (1 relapse occurr-
ed among 16 patients), an unexpected high incidence of oto-
toxicity in high-risk patients who received high-dose cisplatin
(200 mg/m2/cycle, 2 cycles) put us into a major protocol revi-
sion. Thereafter, we have been using a carboplatin-based regi-
men, with which no ototoxicity has occurred. Carboplatin is
known to be less nephrotoxic or ototoxic than cisplatin (24,
25). Considering the high incidence of diabetes insipidus
among patients with CNS-GCTs, cisplatin may not be appro-
priate for those having diabetes insipidus because they should
be controlled with strict input/output balance along with ade-
quate hydration and desmopressin replacement, which is often
very difficult. Almost a half (45.3%) of our patients had dia-
betes insipidus before treatment and ototoxicity occurred in
4 of 10 patients who received high-dose cisplatin. Notably,
3 of 5 patients (60%) who received high-dose cisplatin and
also had diabetes insipidus ultimately developed ototoxicity.
Since our current protocol using carboplatin-based regimen
not only gave rise to excellent survival rate but also were more
tolerable without ototoxicity, we believe that our current car-
boplatin-based chemotherapy protocol is highly effective for
malignant CNS-GCTs.
One of the major limitations of our study is that the radi-
ation guideline was not consistent. Patients in group 2 and
group 3 generally received higher dose of craniospinal irradia-
tion as compared with group 1, although a statistically signif-
icant difference was found only between the low-risk patients
of group 1 and group 3 when matched with each correspond-
ing risk group (Table 1). At any rate, the radiation dose in
our cohort was not any higher than usual doses applied in
other studies-only 10 patients (18.5%) receiving more than
30 Gy of craniospinal irradiation or more than 50 Gy to the
tumor bed (data not shown). Wolden et al. (9) applied 45 to
54 Gy to the tumor bed with or without craniospinal irradi-
ation, which produced approximately 70% of 5-yr disease-
free survival rate, but is still inferior to our results. In a report
by Ogawa et al. (22), the median radiation dose was 50 Gy
to the primary site and 30 Gy to the whole brain and whole
spine, which is also higher than that used in our patients. 
Despite our excellent results for both low-risk and high-
risk patients, we cannot conclude that our current strategy
is also advantageous for low-risk patients because studies using
radiotherapy as a single treatment modality generally have
shown excellent outcomes in pure germinoma. However, we
believe that further reduction of radiation dose might be pos-
sible in selected patients with our current chemotherapy pro-
tocols. 
Although intensive chemotherapy led to a high incidence
of severe myelosuppression and infection, all infectious epi-
sodes following risk-adapted intensive chemotherapy were
manageable with broad-spectrum antibiotics and G-CSF sup-
ports and there were no infection-related major complications.
Because of the rarity of CNS-GCTs, nationwide or multicen-
ter clinical trial is required to determine the efficacy of cur-
rent strategy.
In conclusion, our strategy using short course of risk-adapt-
ed intensive systemic chemotherapy prior to radiotherapy
shows excellent results even in high-risk patients with malig-
nant CNS-GCTs. However, high-dose cisplatin in high-risk
patients causes a high incidence of ototoxicity, especially in
the presence of diabetes insipidus, which favors the use of the
carboplatin-based regimen in that it has lower toxicity pro-
files without the expense of efficacy as shown in our study. 
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